Patents by Inventor Longyan ZHAO

Longyan ZHAO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12280072
    Abstract: A purified oligosaccharide compound having antithrombotic activity or a mixture of a homologous compound thereof and a pharmaceutically acceptable salt thereof, a preparation method for the mixture, a pharmaceutical composition containing the mixture, and uses thereof serving as an intrinsic factor X-enzyme (Xase) inhibitor in the preparation of drugs for preventing and/or treating thrombotic diseases.
    Type: Grant
    Filed: September 28, 2023
    Date of Patent: April 22, 2025
    Assignees: Jiuzhitang Co., Ltd., Mudanjiang YouBo Pharmaceutical Co., Ltd
    Inventors: Jinhua Zhao, Zhenguo Li, Na Gao, Mingyi Wu, Yanming Chen, Longyan Zhao, Yongsheng Wu, Zi Li, Chuang Xiao, Shunliang Zheng, Zhiyuan Nan, Jianbo Zhou, Jianping Xu, Lutan Zhou, Yafang Guo, Hongbo Qin, Jikai Liu
  • Publication number: 20240287214
    Abstract: Chlorella mannogalactan (CM) or a sulfated Chlorella mannogalactan (SCM) compound and application of the SCM compound are disclosed. The CM is obtained by extracting total polysaccharides from Chlorella dry powder before performing separation and purification. The SCM compound is obtained by sulfation modification of the CM. The CM and the SCM compound both consist of mannose, 3-O-methyl-mannose, and galactose. The SCM compound and an excipient thereof form a pharmaceutical composition that can be used as a lyophilized powder injection or an aqueous solution for injection for prevention and/or treatment of thrombotic cardiovascular diseases. The CM or the SCM compound and the application of the SCM compound are adopted. The SCM has good water solubility and strong anticoagulant activity, which can be comparable to enoxaparin sodium.
    Type: Application
    Filed: April 4, 2024
    Publication date: August 29, 2024
    Applicant: GUANGXI UNIVERSITY OF CHINESE MEDICINE
    Inventors: Longyan ZHAO, Qingxia YUAN, Hao TANG, Jinwen HUANG, Kunling LV
  • Publication number: 20240041918
    Abstract: A purified oligosaccharide compound having antithrombotic activity or a mixture of a homologous compound thereof and a pharmaceutically acceptable salt thereof, a preparation method for the mixture, a pharmaceutical composition containing the mixture, and uses thereof serving as an intrinsic factor X-enzyme (Xase) inhibitor in the preparation of drugs for preventing and/or treating thrombotic diseases.
    Type: Application
    Filed: September 28, 2023
    Publication date: February 8, 2024
    Inventors: Jinhua ZHAO, Zhenguo Li, Na Gao, Mingyi Wu, Yanming Chen, Longyan Zhao, Yongsheng Wu, Zi Li, Chuang Xiao, Shunliang Zheng, Zhiyuan Nan, Jianbo Zhou, Jianping Xu, Lutan Zhou, Yafang Guo, Hongbo Qin, Jikai Liu
  • Patent number: 11833169
    Abstract: A purified oligosaccharide compound having antithrombotic activity or a mixture of a homologous compound thereof and a pharmaceutically acceptable salt thereof, a preparation method for the mixture, a pharmaceutical composition containing the mixture, and uses thereof serving as an intrinsic factor X-enzyme (Xase) inhibitor in the preparation of drugs for preventing and/or treating thrombotic diseases.
    Type: Grant
    Filed: January 10, 2017
    Date of Patent: December 5, 2023
    Assignees: MUDANJIANG YOUBO PHARMACEUTICAL CO., LTD., JIUZHITANG CO., LTD.
    Inventors: Jinhua Zhao, Zhenguo Li, Na Gao, Mingyi Wu, Yanming Chen, Longyan Zhao, Yongsheng Wu, Zi Li, Chuang Xiao, Shunliang Zheng, Zhiyuan Nan, Jianbo Zhou, Jianping Xu, Lutan Zhou, Yafang Guo, Hongbo Qin, Jikai Liu
  • Patent number: 11434306
    Abstract: The present disclosure provides a low-molecular-weight Tremella aurantialba glucuronoxylomannan (LTAG) as well as a preparation method and an application thereof, and specifically relates to the technical field of medicine. The LTAG provided in the present disclosure has a weight-average molecular weight of 8,000-24,000 Da. In the method of preparing LTAG as provided in the present disclosure, Tremella aurantialba glucuronoxylomannan is depolymerized by peroxides so as to get low-molecular-weight products, which are then exchanged into pharmaceutically acceptable salts through cation exchange resins. The resulting LTAG has a clear structure, a low viscosity and a good solubility, has a strong immune-enhancing activity, and is capable of acting on TLR4 receptor-activated macrophagocytes and promoting the production of various immune factors, so it can be used in the prevention and/or treatment of immunodeficiency-related diseases.
    Type: Grant
    Filed: January 6, 2021
    Date of Patent: September 6, 2022
    Assignee: GUANGXI UNIVERSITY OF CHINESE MEDICINE
    Inventors: Qingxia Yuan, Longyan Zhao, Hong Li, Ziyi Wei
  • Publication number: 20220041762
    Abstract: The present disclosure provides a low-molecular-weight Tremella aurantialba glucuronoxylomannan (LTAG) as well as a preparation method and an application thereof, and specifically relates to the technical field of medicine. The LTAG provided in the present disclosure has a weight-average molecular weight of 8,000-24,000 Da. In the method of preparing LTAG as provided in the present disclosure, Tremella aurantialba glucuronoxylomannan is depolymerized by peroxides so as to get low-molecular-weight products, which are then exchanged into pharmaceutically acceptable salts through cation exchange resins. The resulting LTAG has a clear structure, a low viscosity and a good solubility, has a strong immune-enhancing activity, and is capable of acting on TLR4 receptor-activated macrophagocytes and promoting the production of various immune factors, so it can be used in the prevention and/or treatment of immunodeficiency-related diseases.
    Type: Application
    Filed: January 6, 2021
    Publication date: February 10, 2022
    Applicant: GUANGXI UNIVERSITY OF CHINESE MEDICINE
    Inventors: Qingxia YUAN, Longyan ZHAO, Hong LI, Ziyi WEI
  • Publication number: 20200254003
    Abstract: A purified oligosaccharide compound having antithrombotic activity or a mixture of a homologous compound thereof and a pharmaceutically acceptable salt thereof, a preparation method for the mixture, a pharmaceutical composition containing the mixture, and uses thereof serving as an intrinsic factor X-enzyme (Xase) inhibitor in the preparation of drugs for preventing and/or treating thrombotic diseases.
    Type: Application
    Filed: January 10, 2017
    Publication date: August 13, 2020
    Inventors: Jinhua ZHAO, Zhenguo Li, Na Gao, Mingyi Wu, Yanming Chen, Longyan Zhao, Yongsheng Wu, Zi Li, Chuang Xiao, Shunliang Zheng, Zhiyuan Nan, Jianbo Zhou, Jianping Xu, Lutan Zhou, Yafang Guo, Hongbo Qin, Jikai Liu
  • Patent number: 10689463
    Abstract: Disclosed are a Fuc3S4S substituted oligoglycosaminoglycan with a weight-average molecular weight (Mw) of about 4.5-9 kD, a pharmaceutical composition containing the Fuc3S4S substituted oligoglycosaminoglycan, a preparation method thereof and a use thereof in preparing medicines for preventing and/or treating thrombotic diseases.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: June 23, 2020
    Assignee: JIUZHITANG CO., LTD.
    Inventors: Jinhua Zhao, Jinxing He, Mingyi Wu, Zhiwen Liu, Na Gao, Longyan Zhao, Zi Li, Feng Lu, Li Xu, Chuang Xiao, Lian Yang, Jun Chen, Lutan Zhou, Wenlie Peng, Jikai Liu
  • Patent number: 10494452
    Abstract: A low-molecular-weight fucosylated glycosaminoglycan (aTFG) containing 2,5-anhydrated talose, alditol, glycosylamine or N-substituted glycosylamine monosaccharide composition thereof, preparation method thereof, pharmaceutical compositions containing the aTFG, and use thereof for preventing and/or treating thrombotic diseases are provided. The aTFG has potent anticoagulant activity targeting at intrinsic coagulation factor Xase, and inhibiting thrombogenesis, and therefore can be used as drugs for preventing and/or treating cardiovascular and cerebrovascular diseases.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: December 3, 2019
    Assignee: Jiuzhitang Co., Ltd.
    Inventors: Jinhua Zhao, Mingyi Wu, Na Gao, Zi Li, Sensen Lai, Longyan Zhao
  • Publication number: 20160347868
    Abstract: Disclosed are a Fuc3S4S substituted oligoglycosaminoglycan with a weight-average molecular weight (Mw) of about 4.5-9 kD, a pharmaceutical composition containing the Fuc3S4S substituted oligoglycosaminoglycan, a preparation method thereof and a use thereof in preparing medicines for preventing and/or treating thrombotic diseases.
    Type: Application
    Filed: December 19, 2014
    Publication date: December 1, 2016
    Inventors: Jinhua ZHAO, Jinxing HE, Mingyi WU, Zhiwen LIU, Na GAO, Longyan ZHAO, Zi LI, Feng LU, Li XU, Chuang XIAO, Lian YANG, Jun CHEN, Lutan ZHOU, Wenlie PENG, Jikai LIU
  • Publication number: 20160060364
    Abstract: A low-molecular-weight fucosylated glycosaminoglycan (aTFG) containing 2,5-anhydrated talose, alditol, glycosylamine or N-substituted glycosylamine monosaccharide composition thereof, preparation method thereof, pharmaceutical compositions containing the aTFG, and use thereof for preventing and/or treating thrombotic diseases are provided. The aTFG has potent anticoagulant activity targeting at intrinsic coagulation factor Xase, and inhibiting thrombogenesis, and therefore can be used as drugs for preventing and/or treating cardiovascular and cerebrovascular diseases.
    Type: Application
    Filed: December 20, 2013
    Publication date: March 3, 2016
    Applicant: KUNMING INSTITUTE OF BOTANY, CHINESE ACADEMY OF SCIENCES
    Inventors: Jinhua ZHAO, Mingyi WU, Na GAO, Zi LI, Sensen LAI, Longyan ZHAO